Clinical trial
A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease
NCT00191373 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191373 |
|---|---|
| Title | A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease |
| Official title | Phase II Study of Gemcitabine and Trastuzumab Therapy in Patients With HER2 Overexpressing Metastatic Breast Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Cancer of the Breast, Breast Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, Trastuzumab |
| Enrollment | 66 |
| Start date | Mar 1, 2002 |
| Completion | Jul 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Sep 12, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: